subscribeSubscribe
Johnson & Johnson Announces Expansion of IMBRUVICA (ibrutinib) Label in the U.S.

Johnson & Johnson Announces Expansion of IMBRUVICA (ibrutinib) Label in the U.S.
PRESS RELEASE
26 Feb 2024
Share Share
An Imbruvica combo regimen could have a new future in MCL

An Imbruvica combo regimen could have a new future in MCL
FIERCE PHARMA
13 Dec 2023
Share Share
New Data Presented at ASH from the Phase 3 GLOW Study Show Fixed-Duration, First-Line Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated an Overall Survival Rate of More Than 84 Percent at 54 Months in Patients with Chronic Lymphocytic Leukaemia

New Data Presented at ASH from the Phase 3 GLOW Study Show Fixed-Duration, First-Line Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated an Overall Survival Rate of More Than 84 Percent at 54 Months in Patients with Chronic Lymphocytic Leukaemia
GLOBENEWSWIRE
11 Dec 2023
Share Share
AbbVie`s Imbruvica-Brukinsa patent suit may have merit: expert

AbbVie`s Imbruvica-Brukinsa patent suit may have merit: expert
Angus Liu FIERCE PHARMA
27 Jun 2023
Share Share
Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL
Caroline Seymour ONCLIVE
20 Jun 2023
Share Share
Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL

Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL
Ryan Scott ONCLIVE
19 Jun 2023
Share Share
NICE signs off on AbbVie, J&J`s Imbruvica-Venclyxta combo in CLL

NICE signs off on AbbVie, J&J`s Imbruvica-Venclyxta combo in CLL
Kevin Dunleavy FIERCE PHARMA
22 Apr 2023
Share Share
NICE gives green light to ibrutinib plus venetoclax for lymphocytic leukaemia

NICE gives green light to ibrutinib plus venetoclax for lymphocytic leukaemia
PHARMIWEB
21 Apr 2023
Share Share
Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications

Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
PRESS RELEASE
07 Apr 2023
Share Share
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation

Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
REUTERS
14 Mar 2023
Share Share